BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lodoco (Colchicine (cardiovascular)) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lodoco (Colchicine (cardiovascular))\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07287345-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 4 readout est. (NCT0728
 7345)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 4.\nStudy: Colchic
 ine's Effect on Inflammatory Markers\nEstimated primary completion: 30 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchicin
 e-cardiovascular#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07287345
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06217120-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 2 readout est. (NCT0621
 7120)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 2\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: Reversing Microvascular Dysfunction in H
 eart Failure With Preserved Ejection Fraction\nEstimated primary completio
 n: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchi
 cine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06217120
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633810-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0563
 3810)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3.\nStudy: COLchic
 ine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of
  Patients With Type 2 Diabetes\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/colchicine-cardiov
 ascular#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05633810
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06396858-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 4 readout est. (NCT0639
 6858)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 4.\nStudy: Anti-in
 flammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaro
 xaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
 \nEstimated primary completion: January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06396858
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05618353-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 4 readout est. (NCT0561
 8353)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 4\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: The Peri-OPerative COlchicine to Reduce 
 Negative Events (POPCORN) Trial\nEstimated primary completion: 31 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/colchicine-cardiov
 ascular#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05618353
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704164-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 2 readout est. (NCT0770
 4164)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 2.\nStudy: Colchic
 ine to Reduce Coronary Artery Inflammation in People With HIV\nEstimated p
 rimary completion: December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/colchicine-cardiovascular#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07704164
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654231-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 2 readout est. (NCT0765
 4231)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 2\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: REducing Systemic Inflammation With LOw-
 dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney 
 Disease: A Pilot Randomized Open-Label Trial\nEstimated primary completion
 : 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchic
 ine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07654231
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930885-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0693
 0885)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: Polypill and Colchicine for Risk Reducti
 on in Atherosclerotic Cardiovascular Disease\nEstimated primary completion
 : May 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colchicin
 e-cardiovascular#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06930885
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232069-1199@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lodoco (Colchicine (cardiovascular)): Phase 3 readout est. (NCT0723
 2069)
DESCRIPTION:Lodoco (Colchicine (cardiovascular))\, phase 3\, Atheroscleroti
 c Cardiovascular Disease.\nStudy: PRE-EMPT: Prospective RandomizEd Evaluat
 ion and Management of Premature aTherosclerosis\nEstimated primary complet
 ion: July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/colch
 icine-cardiovascular#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07232069
URL:https://assetmemo.bio/drug/colchicine-cardiovascular#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
